Clinical Trial

Prostate Cancer Early Detection Using Serial MRI Examinations

Study acronym: PROCEDE
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 21, 2026 (before its estimated January 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
The rationale of the PROCEDE trial is to explore a novel early detection strategy in which biopsy decision does not rely on one single MRI examination, but on the progression of the MRI lesion between 2 consecutive exams, with the objective of reducing the number of unnecessary biopsies, detection of non-clinically prostate cancer and, ultimately, overtreatment.
Trial Details
NCT Number NCT07355504
Lead Sponsor University Hospital, Grenoble
Conditions Prostate Cancer
Enrollment 380 participants
Start Date 2026-01-12
Primary Completion 2026-01-24 (estimated)
Study Completion 2033-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-01-21